UNSPSC 51294515: Azaloxan

This classification denotes an antidepressant agent with the molecular formula C18H25N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0O653FA999, chemically known as (s)-1-(1-(2-(1,4-benzodioxan-2-yl)-ethyl)-4-piperidyl)-2-imidazolidinone but generally known as azaloxan fumarate, which bears US NIH Compound Identifier 6328465. European Medicines Agency schedules azaloxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05631MIG. Most nations schedule azaloxan under HS 29349990 and SITC 51579.

As of Q4 2014, AZALOXAN remains the US FDA Preferred Term for this commodity. Azaloxan bears US NLM identifiers UMLS ID C2698285 and NCI Concept Code C75051. SMILES: C1CN(CCC1N2CCNC2=O)CCC3COC4=CC=CC=C4O3.

UNSPSC 51294515 Azaloxan is a Commodity code, but the recent state and local opportunities tagged under it do not align with azaloxan procurement — instead they reflect a broader pattern of state and local health agencies buying naloxone, safe drug deactivation systems, and generic pharmaceuticals through various contracting mechanisms. The work actually being solicited includes emergency-response medications (naloxone for opioid reversal), drug destruction or neutralization systems, and multi-source generic pharmaceutical and over-the-counter products distributed through wholesaler networks to public health facilities, community health centers, and state employee health plans. Issuing bodies range from single counties (Seminole County, Florida) to state health departments and multi-state cooperative purchasing alliances (Texas HHS Commission, Minnesota Department of Administration). The code shows activity among county health agencies, state Medicaid and pharmacy benefit programs, and multi-state purchasing consortia rather than concentrated single-buyer demand.

Geographic activity appears concentrated in Texas, Florida, and Minnesota based on recent solicitations, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) reaching across multiple states including Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs and pharmacy benefit vendor capabilities; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to state and participating local government health facilities. The MMCAP contract emphasizes cGMP and Drug Supply Chain Security Act compliance, two-year terms with optional extensions, and performance penalties ranging from $200 to $1,500 per violation. The Seminole County procurement requires E-Verify compliance and drug-free workplace certification with a three-month probationary termination clause.